Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) FCF Margin: 2015-2025

Historic FCF Margin for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -558.18%.

  • Intellia Therapeutics' FCF Margin rose 38701.00% to -558.18% in Q3 2025 from the same period last year, while for Sep 2025 it was -717.27%, marking a year-over-year increase of 12536.00%. This contributed to the annual value of -612.78% for FY2024, which is 51216.00% up from last year.
  • Per Intellia Therapeutics' latest filing, its FCF Margin stood at -558.18% for Q3 2025, which was up 20.38% from -701.02% recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' FCF Margin registered a high of 4,933.44% during Q4 2023, and its lowest value of -23,186.67% during Q3 2021.
  • Its 3-year average for FCF Margin is -235.67%, with a median of -701.02% in 2025.
  • Per our database at Business Quant, Intellia Therapeutics' FCF Margin crashed by 2,305,500bps in 2021 and then skyrocketed by 2,256,279bps in 2022.
  • Over the past 5 years, Intellia Therapeutics' FCF Margin (Quarterly) stood at -447.48% in 2021, then plummeted by 24,346bps to -690.94% in 2022, then surged by 562,438bps to 4,933.44% in 2023, then crashed by 560,282bps to -669.38% in 2024, then spiked by 38,701bps to -558.18% in 2025.
  • Its last three reported values are -558.18% in Q3 2025, -701.02% for Q2 2025, and -900.13% during Q1 2025.